PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1384345
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1384345
Immunoglobulin market size is predicted to observe 7.7% CAGR during 2023 and 2032 owing to the escalating incidence of immunodeficiency disorders, including primary immunodeficiency diseases and secondary immunodeficiency diseases. According to a 2021 report by National Library of Medicine, more than 6 million people across the globe are affected by primary immunodeficiencies, of which nearly 70% to 90% are not diagnosed.
The expanding applications of immunoglobulin in treating various autoimmune and inflammatory diseases is bolstering market growth. The ongoing R&D activities in biotechnology are further contributing to the introduction of innovative immunoglobulin products, fostering a competitive market landscape.
The overall immunoglobulin industry is classified based on product type, route of administration, application, end-use, and region.
The IgA product type segment will garner massive revenues by 2032 as immunoglobulin A (IgA) is a key component of the immune system which provides essential defense against infections. IgA is effective in preventing infections in mucosal tissues such as the respiratory and gastrointestinal tracts. As research advances, IgA-based therapies will emerge as a promising avenue in the treatment of various diseases, further solidifying the significance of this segment.
The multifocal motor neuropathy (MMN) segment is anticipated to witness substantial growth through 2032. The rising prevalence of MMN, a rare neurological disorder characterized by muscle weakness and atrophy, is fueling the demand for immunoglobulin therapies. With ongoing clinical trials and research endeavors exploring the efficacy of immunoglobulins in managing MMN symptoms, this application segment is poised to be a lucrative avenue for the market.
Asia Pacific immunoglobulin market is expected to record strong CAGR from 2023 to 2032 owing to the increasing healthcare expenditure, rising prevalence of immunodeficiency disorders, and a growing aging population. Moreover, advancements in the healthcare infrastructure across the region and a surge in awareness regarding the benefits of immunoglobulin therapies are shaping the Asia Pacific industry dynamics.